Video

Dr. Ramasamy discusses clinical trial of nasal testosterone gel

Author(s):

Urology Times staff

“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Ranjith Ramasamy, MD, discusses a clinical trial at his institution evaluating the nasal testosterone gel Nastesto. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.

      Related Videos
      Dr. Ramasamy discusses investigational oral testosterone treatment
      Dr. Ramasamy discusses investigational oral testosterone treatment
      Rido - stock.adobe.com
      A urologist’s view on virtual medicine in men’s health
      Dr. Ramasamy discusses myths about testosterone therapy
      Dr. Ramasamy discusses myths about testosterone therapy
      Around the Practice
      AEs from Novel Hormone Therapy in Nonmetastatic Castrate Resistant Prostate Cancer
      Dr. Ramasamy on 2-year follow-up data of oral testosterone capsule Jatenzo
      Dr. Ramasamy on 2-year follow-up data of oral testosterone capsule Jatenzo
      2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism
      2-year follow-up shows Jatenzo is effective, safe in men with hypogonadism
      Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
      Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
      Related Content
      Use of testosterone does not lead to abnormal hematocrit levels
      November 27th 2023

      Use of testosterone does not lead to abnormal hematocrit levels

      Hannah Clarke
      "The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.
      Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer
      April 21st 2021

      Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer

      Urology Times staff
      Hamilton discusses findings from a recent study published in European Urology.
      Study highlights how DTC online platforms often fail to convey risks of testosterone therapy
      December 8th 2022

      Study highlights how DTC online platforms often fail to convey risks of testosterone therapy

      Northwestern Medicine
      “While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.
      FDA approves oral testosterone replacement therapy for hypogonadism
      August 4th 2022

      FDA approves oral testosterone replacement therapy for hypogonadism

      Urology Times staff
      Kyzatrex is an oral testosterone replacement therapy for the treatment of adult males with conditions associated with hypogonadism.
      Novel testosterone undecanoate capsule launched in US hypogonadism market
      June 9th 2022

      Novel testosterone undecanoate capsule launched in US hypogonadism market

      Jason M. Broderick
      Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.
      FDA approves novel testosterone undecanoate capsule for hypogonadism
      March 29th 2022

      FDA approves novel testosterone undecanoate capsule for hypogonadism

      Jason M. Broderick
      The pivotal trial supporting approval of the oral testosterone undecanoate was Study 16-002, which included 95 hypogonadal males.
      © 2025 MJH Life Sciences

      All rights reserved.